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Epilepsy, the commonest serious neurological condition, is associated with an increased risk in premature deaths, including an
estimated 500 sudden unexpected deaths (SUDEP) per year in the UK. In some patients seizures are associated with cardiac
arrhythmias, which are thought to be a major factor in SUDEP. Omega-3 fatty acids have been shown to reduce cardiac arrhythmias
in animal studies and to reduce sudden cardiac deaths, thought to be due to cardiac arrhythmias, in both healthy subjects and
in those who have had one myocardial infarction. Additionally, omega-3 fatty acids in animal studies and in a small clinical
observation study have shown anti-seizure effects. Omega-3 fatty acid supplementation in patients with refractory seizures may
reduce seizures and seizure associated cardiac arrhythmias and hence SUDEP.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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BACKGROUND
Epilepsy is the commonest serious neurological con-
dition. In the UK between 1 in 140 and 1 in 200 people
(at least 300 000 people) are currently being treated
for epilepsy. People with epilepsy have a 2–3 times
higher risk of premature death than the general pop-
ulation. Every year in the UK about 1000 people die
because of epilepsy, and most of these deaths are as-
sociated with seizures. Sudden unexpected death in
epilepsy or SUDEP is estimated to account for about
500 deaths each year in the UK1.
Epidemiological studies suggest that between 70
and 80% of people developing epilepsy will go into
remission. The remaining patients continue to have
seizures and are refractory to treatment with the cur-
rently available therapies2. It is possible that a number
of factors, including genetics, which are as yet unde-
termined, contribute to the development of intractable
seizures. Nutrition is likely to be one of these factors
and, in particular, deficiency in omega-3 fatty acids
might be an important factor. Nutritional studies sug-
gest that the Western diet is deficient in omega-3 fatty
acids3, which is an essential nutrient. Hence people
with epilepsy in the UK, like those in the general
population, are likely to be deficient in omega-3 fatty
acids. Omega-3 fatty acids have important roles in de-
termining the structural and functional properties of
neuronal membranes, affecting membrane functions
such as electrical signalling, receptor sensitivity and
neurotransmitter release.
SEIZURE ASSOCIATED CARDIAC
ARRHYTHMIAS AND SUDEP
It is recognised that seizures can be associated with
heart rate changes and ECG abnormalities. In one
study of 281 seizures in 81 patients, there was an
increase in heart rate of at least 10 bpm in 73% of
seizures (93% of patients). ECG abnormalities were
found in 26% of seizures (44% of patients), with po-
tentially serious abnormalities (asystole, sinus pause,
ST-segment elevation/depression, T-wave inversion)
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in 29 seizures (11 patients). This study also showed
an increased risk of ECG abnormalities with increased
seizure duration4.
SUDEP in epilepsy is defined as the sudden, un-
expected, witnessed or unwitnessed, non-traumatic
and non-drowning death in patients with epilepsy,
with or without evidence for a seizure, and excluding
documented status epilepticus, in which post-mortem
examination does not reveal a toxicological or
anatomical cause for death. In one case controlled
study, the following were found to be risk factors for
SUDEP: greater number of seizures, greater number
of AEDs, early onset of epilepsy and frequent changes
in AED dosages5. The data suggest that SUDEP is a
seizure-related event.
The cause of SUDEP has not been fully elucidated,
but the death is often thought to be a seizure-related
event. Cardiac tachyarrhythmias, bradyarrhythmias
and sinus arrest, and central hypoventilation which
may result from the release of endogenous opioids
have all been suggested as possible mechanisms6. It is
possible that the cause is multifactorial or is different
in different people. The circumstances of death sug-
gest to us and other authors that cardiac arrhythmias
are likely to be one of the more important causes of
SUDEP7.
ANTI-SEIZURE EFFECTS OF
OMEGA-3 FATTY ACIDS
Studies have shown that the omega-3 fatty acids,
eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) applied extracellularly raise the stimu-
latory thresholds of CA1 neurones in hippocampal
slices8. Infusion of EPA and DHA were equipotent
in raising seizure thresholds in a cortical stimulation
seizure model in the male Wistar rat9. Prolonged oral
administration of alpha-linolenic acid (an omega-3
fatty acid) and linoleic acid in a 1:4 mixture protected
rats from having seizures in four different epilepsy
models10.
Other pharmacological studies show that prosta-
glandin E2 and other pro-inflammatory mediators
are elevated in animal models of epilepsy11, 12. The
enzymes, phospholipase A2 (PLA2) that releases
arachidonic acid from membrane phospholipids, and
oxidoreductase cyclooxygenase-2 (COX2) that con-
verts arachidonic acid to pro-inflammatory mediators,
are activated or induced by seizures13, 14. Anti-
inflammatory steroids reduce pro-inflammatory medi-
ators by inhibiting the expression of COX2 and PLA2
enzymes. ACTH and prednisone are known to reduce
localised and generalised seizures, and are used in
the treatment of a number of intractable epilepsy syn-
dromes. Additionally, increasing anti-inflammatory
mediators appear to have anti-convulsant effects12.
Omega-3 fatty acid EPA reduces pro-inflammatory
mediators by inhibiting PLA215 and COX216 enzymes
and is itself metabolised to the anti-inflammatory
series 3 prostaglandins.
In an open study, five patients with intractable
seizures were given a special spread containing 2.3 g
of DHA and 0.9 g of EPA for 6 months. Three patients
became seizure free and the other two had a greater
than 50% seizure reduction at the end of the trial17.
OMEGA-3 FATTY ACIDS REDUCE CARDIAC
ARRHYTHMIAS AND SUDDEN
CARDIAC DEATHS
In animal feeding studies, omega-3 fatty acids pre-
vented fatal ischaemia-induced cardiac arrhythmias.
Omega-3 fatty acids also prevented such arrhythmias
in surgically prepared, conscious, exercising dogs.
Omega-3 fatty acids have been shown in rat cardiac
myocyte preparations to prevent or terminate tach-
yarrhythmias induced by various arrhythmogenic tox-
ins. The action of omega-3 fatty acids is to stabilise
cardiac myocytes in the heart, increasing by 50% the
stimulus needed to elicit an action potential, and pro-
longing the relative refractory time by approximately
150%18.
The GISSI-Prevenzione trial of 850–882 mg daily
of EPA and DHA in 11 324 patients following a first
myocardial infarction, showed a significant reduction
in cardiovascular deaths (30% reduction) and sud-
den deaths (45% reduction) compared with controls19.
Most patients were already on a risk reduction reg-
imen comprising aspirin, beta-blockers, angiotensin
converting enzyme inhibitors and/or lipid lowering
statins. Time-course analysis of the data showed that
the survival curves for patients receiving EPA and
DHA began to diverge from those of controls early af-
ter randomisation and that total mortality was signif-
icantly lower after 3 months. Increased survival was
predominantly due to a reduction in the risk of sudden
death. The data strongly support an anti-arrhythmic
effect of EPA and DHA20. A study involving 20 551
healthy US physicians demonstrated that those who
consumed fish at least weekly, compared with those
taking it less than monthly, had a lower risk of sudden
cardiac deaths. Sudden cardiac deaths were mainly at-
tributed to cardiac arrhythmias21.
HYPOTHESIS
In a proportion of patients seizures are known to be
associated with the occurrence of cardiac arrhyth-
mias, some of which are potentially serious. The
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circumstances of SUDEP deaths and the lack of
post-mortem findings suggest that cardiac arrhyth-
mias may be an important cause or factor. Higher
intake of EPA and DHA either in the diet or through
supplementation has been shown to reduce sudden
cardiac deaths in healthy subjects and in survivors
of myocardial infarction. We postulate that EPA and
DHA supplementation in patients with intractable
seizures will reduce cardiac arrhythmias associated
with seizures and hence the incidence of SUDEP
in the treated population. This would be in keeping
with anecdotal comments from our Mediterranean
colleagues that SUDEP occurs rarely in their patient
population. The Mediterranean diet is known to con-
tain a higher proportion of omega-3 fatty acids than
the UK diet. As SUDEP is associated with seizures,
reducing total seizure frequency should further con-
tribute to reducing the incidence of SUDEP. EPA and
DHA supplementation appears to have anti-epileptic
effects in animal studies and a preliminary clinical
observation.
TESTING THE HYPOTHESIS
The methodology for testing the anti-epileptic prop-
erties of therapies is well established and trials are
underway to confirm the anti-epileptic effects of EPA
and DHA. The optimal dose of EPA and DHA has yet
to be established. In the one clinical trial reported, the
patients received 2.3 g of DHA and 0.9 g of EPA in a
bread spread17. Review of omega-3 fatty acid supple-
mentation studies suggest that frequently the higher
doses used in trials did not show benefit. In particular,
in a dose ranging study in schizophrenia, 2 g/day of
ethyl-EPA gave the best response whilst 4 g/day was
considerably less effective, and in a study of depres-
sion 1 g/day of ethyl-EPA was more effective than 2
and 4 g/day22. In the GISSI-Prevenzione trial patients
received 850–882 mg of EPA and DHA in a ratio of
EPA:DHA of 1:219. These data may suggest that the
optimal total daily dose of EPA and DHA for peo-
ple with epilepsy is likely to be between 850 and
2000 mg. In one of the on-going trials to confirm the
anti-epileptic effects of EPA and DHA, a total daily
dose of 1700 mg (EPA:DHA of 3:2) is administered
as six capsules.
Patients with epilepsy who have been identified
through Holter or Reveal implantable loop recorder
monitoring to have cardiac arrhythmias can be stud-
ied in controlled trials to examine the effect of EPA
and DHA on the frequency of seizure-related arrhyth-
mias. The definitive way to test this hypothesis is to
randomise large groups of patients with intractable
epilepsy to receive EPA and DHA supplementation.
In the novel anti-epileptic drug trial programmes in
patients with intractable seizures, SUDEP rates of
2.8–3.9 per 1000 person years are observed23. If EPA
and DHA supplementation were to reduce this rate
from 4 to 1 per 1000 person years, then 6000 patients
treated for a year per treatment arm would be required
to detect this difference with 90% power at the 5%
level of significance. This is using the log rank test in
survival analysis that treats deaths from other causes
as censored observations.
The above hypothesis supports the exhortation ‘Let
your food be your medicine’ and reflects the increasing
attention that medicine is focusing on nutrition in the
overall management of health.
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